Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $36.00 by Analysts at The Goldman Sachs Group

Viridian Therapeutics (NASDAQ:VRDN) had its price target cut by The Goldman Sachs Group from $41.00 to $36.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

VRDN has been the topic of several other reports. Truist Financial lowered their target price on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wedbush reduced their price target on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating on the stock in a research report on Tuesday. Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wells Fargo & Company dropped their price objective on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, UBS Group started coverage on Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price for the company. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Trading Up 5.6%

VRDN stock opened at $19.56 on Tuesday. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29. The company has a market capitalization of $2.00 billion, a PE ratio of -5.95 and a beta of 1.00. The company’s 50-day simple moving average is $29.16 and its 200 day simple moving average is $27.89. The company has a debt-to-equity ratio of 0.08, a quick ratio of 12.65 and a current ratio of 12.65.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. As a group, sell-side analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Trading of Viridian Therapeutics

Several large investors have recently made changes to their positions in VRDN. Vanguard Group Inc. increased its stake in Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after acquiring an additional 1,280,161 shares during the last quarter. Commodore Capital LP lifted its stake in Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter. State Street Corp lifted its stake in Viridian Therapeutics by 35.7% during the fourth quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after purchasing an additional 912,394 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Viridian Therapeutics by 42.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock valued at $107,036,000 after purchasing an additional 1,021,310 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 108.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after purchasing an additional 1,580,303 shares in the last quarter.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.